联合MRI靶向与系统穿刺活检改善前列腺癌主动监测风险分层
该研究评估联合MRI靶向加系统12针穿刺活检(Cbx)在筛选主动监测(AS)患者中的效用。579例GG1或GG2前列腺癌患者接受确认性Cbx,43.2%升级,19.2%升级至≥GG3。随访226例AS患者,28.8%进展至≥GG3,中位失败时间89个月;仅年龄和Cbx的GG是AS失败预测因子。
要点
- 确认性联合活检使43.2%患者升级,19.2%升至≥GG3。
- AS随访中28.8%进展至≥GG3,中位失败时间89个月。
- Cbx的GG和年龄是AS失败的独立预测因子。
核心结论
- 联合MRI靶向加系统穿刺活检为AS入组时的风险分层提供有用信息。
研究设计与样本
- 回顾性队列研究,纳入2007年7月至2020年1月579例GG1或GG2前列腺癌患者,均接受MRI和确认性Cbx。
主要发现
- 579例中79.3%(459/579)初始GG1,20.7%(120/579)GG2。
- 43.2%(250/579)在确认性Cbx上升级,19.2%(111/579)升级至≥GG3。
- 226例AS随访患者中,Cbx结果良性32.7%(74/226)、GG1 45.6%(103/226)、GG2 21.7%(49/226)。
- 28.8%(65/226)最终进展至≥GG3,中位AS失败时间89个月。
- 阴性、GG1、GG2组中位进展时间分别为97、97、32个月(p < .001)。
临床怎么用
- 对考虑主动监测的前列腺癌患者,推荐联合MRI靶向加系统穿刺活检以改善风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of combined MRI-targeted plus systematic 12-core biopsy (Cbx) to aid in the selection of patients for active surveillance (AS). METHODS: From July 2007 to January 2020, patients with Gleason Grade Group (GG) 1 or GG 2 prostate cancer were referred to our center for AS consideration. All patients underwent an MRI and confirmatory combined MRI-targeted plus systematic biopsy (Cbx), and AS outcomes based on Cbx results were compared. Cox regression was used to identify predictors of AS failure, defined as progression to ≥ GG3 disease on follow-up biopsies. RESULTS: Of 579 patients referred for AS, 79.3% (459/579) and 20.7% (120/579) had an initial diagnosis of GG1 and GG2 disease, respectively. Overall, 43.2% of patients (250/579) were upgraded on confirmatory Cbx, with 19.2% (111/579) upgraded to ≥ GG3. For the 226 patients followed on AS, 32.7% (74/226) had benign, 45.6% (103/226) had GG1, and 21.7% (49/226) had GG2 results on confirmatory Cbx. In total, 28.8% (65/226) of patients eventually progressed to ≥ GG3, with a median time to AS failure of 89 months. The median time from confirmatory Cbx to AS failure for the negative, GG1, and GG2 groups were 97, 97, and 32 months, respectively (p < .001). On multivariable regression, only age (hazard ratio 1.06 [1.02-1.11], p < .005) and GG on confirmatory Cbx (hazard ratio 2.75 [1.78-4.26], p < .005) remained as positive predictors of AS failure. CONCLUSION: The confirmatory combined MRI-targeted plus systematic biopsy provides useful information for the risk stratification of patients at the time of AS enrollment.
引用
- O'Connor LP, Wang AZ, Yerram NK, et al. Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer. Urology. 2020. PMID: 32679272. doi:10.1016/j.urology.2020.06.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。